A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
BRUKER CORP
BRKR
$9.1B
Mkt Cap
$60.45
-2.74%
BRUKER CORP (BRKR) has a 5-year average return on invested capital (ROIC) of 13.3%. This indicates solid capital allocation.
BRUKER CORP (BRKR) has a market capitalization of $9.2B. It is classified as a mid-cap stock.
Yes, BRUKER CORP (BRKR) pays a dividend with a trailing twelve-month yield of 0.25%.
BRUKER CORP (BRKR) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
BRUKER CORP (BRKR) reported annual revenue of $3.4 billion in its most recent fiscal year, based on SEC EDGAR filings.
BRUKER CORP (BRKR) has a net profit margin of -0.7%. The company is currently unprofitable.
BRUKER CORP (BRKR) generated $43 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Bruker is a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. The company operates through four reportable segments: BSI BioSpin (magnetic resonance spectroscopy, preclinical imaging, biopharma and applied solutions, services and lifecycle support, integrated data solutions, and automation), BSI CALID (chemicals, applied markets, life science, in-vitro diagnostics, and detection), BSI NANO (spatial biology, semiconductor metrology, and related technologies), and BEST (superconducting technologies and research instruments). Bruker's technology platforms include magnetic resonance, mass spectrometry, gas and liquid chromatography, X-ray, microscopy, metrology, and molecular spectroscopy, which enable customers to determine molecular structure, dynamics, and function. The company serves academic and government research facilities, pharmaceutical and biotechnology companies, battery and chemical manufacturers, food and beverage producers, clinical and polymer companies, and nonprofit laboratories across North America, Europe, and globally. Bruker's business model combines instrument sales with recurring aftermarket revenue through services and lifecycle support, with aftermarket revenue representing 38% of BSI revenues as of 2025. The company differentiates through innovation in post-genomic disease biology research solutions, structural proteomics, drug discovery, and molecular diagnostics, with a focus on expanding into high-potential markets and driving recurring revenue through connected services and automation.
【Organic growth recovery underway】 Management expects organic revenue growth to resume in the second quarter of 2026 following a mid-single-digit decline in the first quarter, with low to mid-single-digit organic growth anticipated for Q2 and continued sequential improvements through the remainder of the year. The company is executing significant cost-saving initiatives expected to exceed $140 million in annualized savings, with the majority of benefits reflected in the second half of 2026 and beyond, driving substantial operating margin expansion despite foreign exchange and tariff headwinds. Management remains optimistic about improved U.S. academic funding following NIH budget increases and expects strengthening demand in biopharma, diagnostics, and semiconductor metrology end markets, with order momentum in the BSI segment supporting confidence in achieving guidance. Beyond 2026, the company targets a return to organic growth 200–300 basis points above market growth rates and aims to achieve EBITDA margins exceeding 25% over time, with continued major margin expansion steps planned for 2027 and 2028.
| Metric | Target | Period |
|---|---|---|
| Reported Revenue | $3.57 billion–$3.60 billion | FY2026 |
| Organic Revenue Growth | 1%–2% | FY2026 |
| Non-GAAP Operating Margin Expansion | 250–300 basis points | FY2026 |
| Non-GAAP EPS | $2.10–$2.15 | FY2026 |
Reported Revenue (FY2026): “Reported revenue of $3.57 billion-$3.60 billion, representing reported growth of 4%-5% compared to fiscal year 2025.”
Organic Revenue Growth (FY2026): “Organic revenue growth of 1%-2% year-over-year”
Non-GAAP Operating Margin Expansion (FY2026): “resulting in a non-GAAP operating margin expansion of 250 to 300 basis points compared to the 12.6% operating margin posted in fiscal year 2025.”
Non-GAAP EPS (FY2026): “non-GAAP EPS for fiscal year 2026 in a range of $2.10-$2.15 or non-GAAP EPS growth of 15%-17% compared to fiscal year 2025.”
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call, Q2 FY2025 Earnings Call, Q1 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 3.5B | 3.4B | 3.4B | 3.0B | 2.5B | 2.4B |
| Net Income | -36M | -23M | 113M | 427M | 297M | 277M |
| EPS | $-0.24 | $-0.15 | $0.76 | $2.90 | $1.99 | $1.81 |
| Free Cash Flow | 51M | 43M | 136M | 243M | 145M | 190M |
| ROIC | 0.9% | 1.0% | 4.5% | 14.5% | 20.9% | 25.5% |
| Gross Margin | 45.3% | 45.9% | 49.0% | 51.0% | 51.6% | 50.0% |
| Debt/Equity | 0.68 | 0.83 | 1.28 | 1.55 | 1.14 | 1.25 |
| Dividends/Share | $0.15 | $0.15 | $0.20 | $0.20 | $0.16 | $0.16 |
| Operating Income | 47M | 68M | 253M | 437M | 433M | 413M |
| Operating Margin | 1.3% | 2.0% | 7.5% | 14.7% | 17.1% | 17.1% |
| ROE | -1.5% | -1.1% | 7.2% | 34.3% | 27.2% | 27.3% |
| Shares Outstanding | 152M | 150M | 149M | 147M | 149M | 153M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 1.8B | 1.6B | 1.6B | 1.8B | 1.9B | 2.1B | 2.0B | 2.4B | 2.5B | 3.0B | 3.4B | 3.4B | 3.5B |
| Gross Margin | 42.2% | 43.6% | 46.3% | 46.2% | 47.5% | 48.0% | 47.3% | 50.0% | 51.6% | 51.0% | 49.0% | 45.9% | 45.3% |
| R&D | 174M | 146M | 148M | 162M | 173M | 188M | 198M | 221M | 236M | 295M | 377M | 395M | 399M |
| SG&A | 451M | 392M | 390M | 415M | 445M | 500M | 469M | 561M | 607M | 729M | 894M | 947M | 963M |
| EBIT | 105M | 146M | 182M | 220M | 262M | 301M | 248M | 413M | 433M | 437M | 253M | 68M | 47M |
| Op. Margin | 5.8% | 9.0% | 11.3% | 12.4% | 13.8% | 14.5% | 12.5% | 17.1% | 17.1% | 14.7% | 7.5% | 2.0% | 1.3% |
| Net Income | 57M | 102M | 154M | 79M | 180M | 197M | 158M | 277M | 297M | 427M | 113M | -23M | -36M |
| Net Margin | 3.1% | 6.3% | 9.5% | 4.5% | 9.5% | 9.5% | 7.9% | 11.5% | 11.7% | 14.4% | 3.4% | -0.7% | -1.1% |
| Non-Recurring | 44M | 30M | 22M | 17M | 10M | 12M | 19M | 12M | 18M | 31M | 20M | 174M | 85M |
| Returns on Capital | |||||||||||||
| ROIC | 9.0% | 20.1% | 24.2% | 16.1% | 20.1% | 15.2% | 12.5% | 25.5% | 20.9% | 14.5% | 4.5% | 1.0% | 0.9% |
| ROE | 7.0% | 13.6% | 21.7% | 11.1% | 22.2% | 21.9% | 16.9% | 27.3% | 27.2% | 34.3% | 7.2% | -1.1% | -1.5% |
| ROA | 2.9% | 5.7% | 8.7% | 4.2% | 8.8% | 8.0% | 5.4% | 8.3% | 8.2% | 10.9% | 2.2% | -0.4% | -0.6% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 114M | 229M | 131M | 154M | 240M | 213M | 332M | 282M | 274M | 350M | 251M | 134M | 140M |
| Free Cash Flow | 81M | 195M | 94M | 111M | 191M | 140M | 235M | 190M | 145M | 243M | 136M | 43M | 51M |
| Owner Earnings | 45M | 168M | 67M | 80M | 163M | 128M | 236M | 176M | 158M | 204M | 42M | -106M | -108M |
| CapEx | 34M | 34M | 37M | 44M | 49M | 73M | 97M | 92M | 129M | 107M | 115M | 91M | 89M |
| Maint. CapEx | 60M | 53M | 54M | 64M | 65M | 76M | 80M | 89M | 89M | 115M | 184M | 220M | 228M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 17M | 2.9M | 40M | 0 | 0 | 0 | 0 |
| D&A | 60M | 53M | 54M | 64M | 65M | 76M | 80M | 89M | 89M | 115M | 184M | 220M | 228M |
| CapEx/OCF | 29.6% | 14.9% | 28.4% | 28.3% | 20.5% | 34.2% | 29.3% | 32.6% | 47.1% | 30.5% | 45.9% | 67.7% | 63.4% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 26M | 25M | 25M | 25M | 25M | 24M | 30M | 29M | 30M | 23M | 23M |
| Dividend Yield | N/A | N/A | 0.7% | 0.6% | 0.5% | 0.4% | 0.4% | 0.2% | 0.3% | 0.3% | 0.3% | 0.4% | 0.2% |
| Share Buybacks | 0 | 90M | 160M | 152M | 0 | 142M | 123M | 153M | 263M | 152M | 0 | 10M | 0 |
| Buyback Yield | N/A | 2.3% | 4.8% | 2.8% | N/A | 1.8% | 1.5% | 1.2% | 2.7% | 1.4% | N/A | 0.1% | 0.0% |
| Stock-Based Comp | 9.4M | 8.0M | 9.4M | 11M | 11M | 9.6M | 16M | 17M | 28M | 31M | 25M | 20M | 20M |
| Debt Repayment | 800K | 600K | 100K | 0 | 0 | 15M | 0 | 800K | 111M | 24M | 135M | 467M | 467M |
| Balance Sheet | |||||||||||||
| Net Debt | -143M | -161M | 57M | 171M | 133M | 859M | 113M | 166M | 625M | 1.6B | 2.1B | 1.7B | 1.5B |
| Cash & Equiv. | 320M | 267M | 342M | 325M | 322M | 678M | 682M | 1.1B | 646M | 488M | 183M | 299M | 133M |
| Long-Term Debt | 354M | 265M | 392M | 416M | 323M | 813M | 842M | 1.2B | 1.2B | 1.2B | 2.1B | 1.9B | 1.7B |
| Debt/Equity | 0.46 | 0.42 | 0.81 | 0.84 | 0.51 | 1.70 | 0.88 | 1.25 | 1.14 | 1.55 | 1.28 | 0.83 | 0.68 |
| Interest Coverage | 7.9 | 11.2 | 13.8 | 14.3 | 20.8 | 18.8 | 17.2 | 28.9 | 26.9 | 26.6 | 5.3 | 1.1 | 93.2 |
| Equity | 766M | 726M | 686M | 725M | 897M | 907M | 961M | 1.1B | 1.1B | 1.4B | 1.8B | 2.5B | 2.5B |
| Total Assets | 1.9B | 1.7B | 1.8B | 1.9B | 2.1B | 2.8B | 3.0B | 3.6B | 3.6B | 4.2B | 5.8B | 6.2B | 6.1B |
| Total Liabilities | 1.1B | 997M | 1.1B | 1.2B | 1.2B | 1.9B | 2.1B | 2.6B | 2.5B | 2.8B | 4.0B | 3.7B | 11M |
| Intangibles | 84M | 75M | 70M | 82M | 219M | 233M | 229M | 212M | 271M | 331M | 913M | 900M | 902M |
| Retained Earnings | 656M | 757M | 885M | 942M | 1.1B | 1.3B | 1.4B | 1.7B | 1.9B | 2.3B | 2.4B | 2.4B | 2.4B |
| Working Capital | 784M | 677M | 751M | 834M | 705M | 1.2B | 1.1B | 1.5B | 1.2B | 962M | 772M | 933M | 749M |
| Current Assets | 1.4B | 1.2B | 1.3B | 1.4B | 1.3B | 1.8B | 1.9B | 2.5B | 2.1B | 2.2B | 2.1B | 2.2B | 2.1B |
| Current Liabilities | 583M | 555M | 525M | 525M | 599M | 646M | 792M | 939M | 914M | 1.2B | 1.3B | 1.3B | 1.4B |
| Per Share Data | |||||||||||||
| EPS | 0.33 | 0.60 | 0.95 | 0.49 | 1.14 | 1.26 | 1.02 | 1.81 | 1.99 | 2.90 | 0.76 | -0.15 | -0.24 |
| Owner EPS | 0.26 | 0.99 | 0.42 | 0.50 | 1.04 | 0.82 | 1.52 | 1.15 | 1.06 | 1.39 | 0.28 | -0.71 | -0.71 |
| Book Value | 4.46 | 4.29 | 4.25 | 4.52 | 5.69 | 5.79 | 6.21 | 6.99 | 7.47 | 9.35 | 11.97 | 16.38 | 16.21 |
| Cash Flow/Share | 0.67 | 1.35 | 0.81 | 0.96 | 1.52 | 1.36 | 2.15 | 1.84 | 1.84 | 2.38 | 1.69 | 0.89 | 1.26 |
| Dividends/Share | N/A | N/A | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 | 0.20 | 0.20 | 0.15 | 0.15 |
| Shares Out. | 171.8M | 169.3M | 161.7M | 160.4M | 157.6M | 156.5M | 154.7M | 153.1M | 149.0M | 147.3M | 148.8M | 150.0M | 152.2M |
| Valuation | |||||||||||||
| P/E Ratio | 57.2 | 39.0 | 21.6 | 68.3 | 25.0 | 39.7 | 51.9 | 44.7 | 33.0 | 25.2 | 76.5 | N/A | -250.7 |
| P/FCF | 40.3 | 20.3 | 35.4 | 48.5 | 23.5 | 55.7 | 34.9 | 65.1 | 67.4 | 44.3 | 63.6 | 166.3 | 179.4 |
| EV/EBIT | 29.4 | 25.8 | 18.3 | 24.3 | 17.2 | 26.4 | 33.5 | 30.7 | 22.5 | 25.7 | 41.1 | 124.5 | 230.5 |
| Price/Book | 4.2 | 5.5 | 4.8 | 7.4 | 5.0 | 8.6 | 8.5 | 11.6 | 8.8 | 7.8 | 4.9 | 2.9 | 3.7 |
| Price/Sales | 1.9 | 2.0 | 2.3 | 2.4 | 2.6 | 3.1 | 3.3 | 4.6 | 3.7 | 3.4 | 3.1 | 1.8 | 2.7 |
| FCF Yield | 2.5% | 4.9% | 2.8% | 2.1% | 4.2% | 1.8% | 2.9% | 1.5% | 1.5% | 2.3% | 1.6% | 0.6% | 0.6% |
| Market Cap | 3.2B | 4.0B | 3.3B | 5.4B | 4.5B | 7.8B | 8.2B | 12.4B | 9.8B | 10.8B | 8.6B | 7.2B | 9.2B |
| Avg. Price | 20.19 | 19.00 | 23.23 | 26.77 | 31.03 | 41.67 | 42.99 | 71.94 | 62.70 | 69.20 | 69.34 | 41.94 | 60.45 |
| Year-End Price | 18.88 | 23.37 | 20.50 | 33.46 | 28.45 | 49.99 | 52.96 | 80.94 | 65.65 | 73.22 | 58.12 | 48.01 | 60.45 |
BRUKER CORP passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 212.5x vs a median of 48.5x. The company's 5-year average ROIC is 13.3% with a gross margin of 49.5%. Total shareholder yield (dividends) is 0.2%. At current prices, the estimated annualized return to fair value is -9.5%.
BRUKER CORP (BRKR) has a debt-to-equity ratio of 0.83. This indicates moderate leverage.
BRUKER CORP (BRKR) reported earnings per share (EPS) of $-0.15 in its most recent fiscal year.
BRUKER CORP (BRKR) has a return on equity (ROE) of -1.1%. A negative ROE may indicate losses or negative equity.
BRUKER CORP (BRKR) has a 5-year average gross margin of 49.5%. This indicates decent pricing power.
The Ledger Terminal provides 17 years of financial data for BRUKER CORP (BRKR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BRUKER CORP (BRKR) has a book value per share of $16.38, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management expects organic revenue growth to resume in the second quarter of 2026 following a mid-single-digit decline in the first quarter, with low to mid-single-digit organic growth anticipated for Q2 and continued sequential improvements through the remainder of the year. The company is executing significant cost-saving initiatives expected to exceed $140 million in annualized savings, with the majority of benefits reflected in the second half of 2026 and beyond, driving substantial operating margin expansion despite foreign exchange and tariff headwinds. Management remains optimistic about improved U.S. academic funding following NIH budget increases and expects strengthening demand in biopharma, diagnostics, and semiconductor metrology end markets, with order momentum in the BSI segment supporting confidence in achieving guidance. Beyond 2026, the company targets a return to organic growth 200–300 basis points above market growth rates and aims to achieve EBITDA margins exceeding 25% over time, with continued major margin expansion steps planned for 2027 and 2028.
Based on recent SEC filings and earnings calls, BRUKER CORP (BRKR) has provided the following forward guidance: Reported Revenue: $3.57 billion–$3.60 billion (FY2026); Organic Revenue Growth: 1%–2% (FY2026); Non-GAAP Operating Margin Expansion: 250–300 basis points (FY2026); Non-GAAP EPS: $2.10–$2.15 (FY2026).
No recent press releases.